

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 May 2003 (15.05.2003)

PCT

(10) International Publication Number
WO 03/039531 A1

(51) International Patent Classification⁷: **A61K 31/18**,
9/20, 9/28, 9/48, A61P 13/08

Castelló 1, Poligno Las Salinas, E-08830 San Boi de Llobregat (ES).

(21) International Application Number: PCT/NL02/00710

(74) Agent: **PRINS, Hendrik, Willem**; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).

(22) International Filing Date:
6 November 2002 (06.11.2002)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/331,055 7 November 2001 (07.11.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **SYNTHON B.V.** [NL/NL]; Microweg 22, NL-6545 CM Nijmegen (NL).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LEMMENS, Jacobus, Maria** [NL/NL]; Lodewijkstraat 30, NL-6585 KM Mook (NL). **PLATTEEUW, Johannes, Jan** [NL/NL]; Dommelstraat 215, NL-5215 BL 's-Hertogenbosh (NL). **VAN DALEN, Frans** [NL/NL]; Groesbeekseweg 11, NL-6524 CK Nijmegen (NL). **ORTEGA, Arturo, Siles** [ES/ES]; Caselló 1, Poligno Las Salinas, E-08830 San Boi de Llobregat (ES). **ESCOI, Juan, Cucala** [ES/ES];

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MODIFIED RELEASE TAMSULOSIN TABLETS

(57) Abstract: The present invention is directed towards modified release tablets comprising a tablet matrix having dispersed therein tamsulosin or a pharmaceutically acceptable salt thereof and optionally having an enteric coating over said matrix with a dissolution profile such that in each of the media SIF, FaSSIF, and FeSSIF said tablet releases not more than 60% of said tamsulosin at 2 hours elapsed time in USP 2 apparatus using 500 ml of said media at 50-100 rpm paddle speed.



WO 03/039531 A1


MODIFIED RELEASE TAMSULOSIN TABLETS

This application claims the benefit of priority under 35 U.S.C. § 119(e) from prior U.S. provisional application 60/331,055, filed November 7, 2001, the entire contents of which are incorporated herein by reference.

5 BACKGROUND OF THE INVENTION

The present invention relates to modified release tamsulosin tablets that exhibit little or no food effect and to unit dosage forms made therefrom.

Tamsulosin is the common name for 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-benzenesulfonamide of the formula (1).



10

It is disclosed in EP 34432 and US 4731478 as a pharmaceutically active substance having alpha-adrenergic blocking activity that is useful for treatment of cardiac insufficiencies and benign prostatic hyperplasia.

(R)-tamsulosin hydrochloride is marketed under various tradenames, including
15 FLOMAX[®] (Boehringer Ingelheim) in the U.S., HARNAL[®] (Yamanouchi) in Japan and OMNIC[®] (Yamanouchi) in Europe, for treatment of symptoms of benign prostatic hyperplasia (also known as BPH) such as urinary volume and frequency problems. The approved drug products include a capsule dosage form for oral administration that comprises 0.4 mg of the tamsulosin hydrochloride. The capsule provides controlled

release of the tamsulosin and is a once daily dosage form, although two capsules can be used if needed; i.e. a maximum single daily administration of 0.8 mg.

The controlled or modified release commercialized capsule form suffers from a drawback in that it exhibits a food effect. A food effect refers to the difference in
5 bioabsorption or bioavailability of a drug arising from administration to a fasting patient (an empty stomach) versus a fed patient (food in the stomach). For the commercial capsule, the food effect is rather pronounced. For example, it is reported in the labeling information for FLOMAX[®] that under fasted conditions the Tmax is 4-5 hours, but the Tmax under fed conditions is 6-7 hours. Taking the capsules under
10 fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (Cmax) compared to fed conditions. Thus, when taken after a meal, the tamsulosin achieves a lower maximum blood plasma concentration; and this peak is achieved later in time. Accordingly, administering after a meal provides a flatter and more controlled release blood plasma profile in
15 comparison to administering under fasting conditions, albeit with a loss in bioavailability.

The commercial capsule labeling instructs the administration to occur in a fed state: after a meal (Japan), after breakfast (Europe) and 30 minutes after the same meal each day (U.S.). It is believed that this dosing is recommended because it provides
20 more consistent results and fewer side effects. Indeed, even though the absorption of the tamsulosin is better under fasted conditions (90+%) than fed conditions, the approved use directs that the tamsulosin capsule be administered under fed conditions.

The commercial capsule form of tamsulosin is believed to correspond to U.S. 4,772,475 (EP 194838, EP 533297). U.S. 4,772,475 discloses controlled-release pharmaceutical dosage forms comprising multiple granulate units containing tamsulosin, microcrystalline cellulose and a release control agent. The granulate
5 gradually releases tamsulosin from the granulate matrix. No discussion occurs surrounding the food effect issue.

Because of the food effect in the commercial capsule tamsulosin product, a patient that takes the capsule while fasting (without a meal) is potentially more likely to experience undesirable side-effects such as dizziness, rhinitis, and/or abnormal
10 ejaculation. It would be beneficial to make a tamsulosin pharmaceutical dosage form that exhibits reduced, little, or even no food effect. In this way, the dosage form would be safer; i.e. even if taken under fasted conditions, the risk of side effects is lessened. Although the food effect of the commercial tamsulosin capsule is well documented, no solution to the food effect problem has been provided thus far.

SUMMARY OF THE INVENTION

It has now been discovered that a modified release tamsulosin tablet can be formed that has reduced food effect. Accordingly one aspect of the invention relates to a pharmaceutical tablet comprising a tablet matrix having dispersed therein 0.1 to
20 10 mg of tamsulosin or a pharmaceutically acceptable salt thereof, and optionally having an enteric coating over the matrix. The tablet is a modified release tablet and exhibits a dissolution profile such that in each of the media SIF, FaSSIF, and FeSSIF,

each hereinafter defined, the tablet releases not more than 60% of the tamsulosin at 2 hours elapsed time in USP 2 apparatus using 500 ml of the media at 50-100 rpm paddle speed. Preferably the tablet releases at least 20% of the tamsulosin by the 2 hour mark, again in each of the three media. The media serve to model *in vitro* the
5 intestinal conditions encountered *in vivo*, with FaSSIF corresponding to a fasting state and FeSSIF corresponding to a fed state. By having less than 60% of the tamsulosin released at 2 hours under each of the simulated conditions, the tablet demonstrates that neither fed nor fasting conditions are likely to reduce the modified release nature of the drug product.

10 Another aspect of the invention relates to a monolithic pharmaceutical tablet, comprising 0.1 to 10 mg of tamsulosin or a pharmaceutically acceptable salt thereof, 10 wt% - 90 wt% hydroxypropyl methylcellulose, and a total tablet weight of 10 to 300 mg. The tablet preferably exhibits reduced food effect and more preferably meets the dissolution profile requirements described above.

15 In each of these aspects, the tablets can be administered per se, optionally with an enteric coating, but preferably without an enteric coating, or one or more tablets can be encapsulated and administered as one or more capsules. A further aspect of the invention relates to a method for treating the symptoms of benign prostatic hyperplasia, which comprises administering to a patient in need thereof one or more of
20 the above tablets.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is the release curves of tamsulosin capsules manufactured by Yamanouchi Europe in the four described media.

FIG.2 is the release curves of tamsulosin tablets (batch G) in the four described media.

5 FIG.3 is the release curves of tamsulosin tablets (batch H) in the four described media.

FIG.4 is the release curves of tamsulosin enteric coated tablets (batch G) in the four described media.

FIG.5 is the release curves of tamsulosin enteric coated tablets (batch H) in the four described media.

10 FIG.6 is the release curves of tamsulosin uncoated and coated tablets (batch N) in selected media.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to modified release tamsulosin tablets and to capsules containing the same. "Modified release" is used herein in a broad sense and means any dosage form that is not an immediate release dosage form; i.e., not a dosage form that releases in a dissolution test at least 75% of the tamsulosin within the first 30 minutes in a standard dissolution test (i.e. USP apparatus 2, paddles at 50 rpm, with 500 ml SGF at 37°C). The tablets exhibit a reduced food effect in comparison to the commercially available tamsulosin capsules. Unlike these capsules, the present

15

20

invention is based on the discovery that tamsulosin or its pharmaceutically acceptable salt can be formulated into a tablet having controllable food effect properties.

The tamsulosin tablets preferably exhibit a dissolution profile such that in each of SIF, FaSSIF, and FeSSIF, no more than 60%, preferably 20% to 60%, of the tamsulosin is released at 2 hours. The dissolution test is run with paddles at 50-100 rpm, preferably at 100 rpm, in USP apparatus 2 using 500 ml of the media in which the test is being conducted. In certain embodiments, especially those involving uncoated tablets, the dissolution profile further includes releasing no more than 60%, preferably 20% to 60%, of the tamsulosin in 500 ml of SGF at 2 hours is released in USP apparatus 2, paddles at 50-100 rpm, preferably at 100 rpm. In all dissolution tests for determining the release profile for purposes of the present invention, the media is at a temperature of 37 °C. 500 ml of media is used, assuming one tablet is placed in the apparatus, because it is believed to provide more accurate modeling/prediction of the *in vivo* result.

The dissolution mediums, for purposes of this invention, are defined as follows:

SGF (USP Simulated Gastric Fluid without pepsin) composition:

HCl	qs	pH 1.2
NaCl		0.2 %
water	qs	1000 ml

SIF (USP Simulated Intestinal Fluid without pancreatin) composition:

KH ₂ PO ₄		6.8 g
NaOH	qs	pH 6.8

water qs 1000 ml

FeSSIF (Simulated Intestinal Fluid, Fed State) Composition:

	Acetic acid		0.144M
5	NaOH	qs	pH 5
	Na Taurocholate		15 mM
	Lecithin		4 mM
	KCl		0.19 M
	distilled water	qs	1000 ml

10 pH=5

osmolarity=485-535 mOsm

buffer capacity= 75±2 mEQ/L/pH

FaSSIF (Simulated Intestinal Fluid, Fasting State) Composition:

15	KH ₂ PO ₄		0.029 M
	NaOH	qs	pH 6.8
	Na Taurocholate		5 mM
	Lecithin		1.5 mM
	KCl		0.22 M
20	distilled water	qs	1000 ml

pH=6.8

osmolarity=280-310 mOsm

buffer capacity= 10±2 mEQ/L/pH

25 SGF represents a standard stomach condition. SIF represents a standard intestinal condition. FeSSIF is tailored to better represent the fed state while FaSSIF is tailored to better represent the fasting state. Note that not only are the pH different, but equally important, the osmolarity are also different. FaSSIF and FeSSIF media have

been generally used to describe *in vitro* - *in vivo* correlations for immediate release lipophilic, poorly water-soluble drugs (i.e. ketoconazole, danazol, atovaquone, troglitazone, mefenamic acid) but none of the previous studies suggest the application to a modified release low dose composition, and soluble drug such as tamsulosin HCl
5 (volume of any aqueous media needed to dissolve until 10 mg is not more than 500 ml.), neither to a modified-release formulation (including controlled, extended or delayed release).

As shown in the subsequent reference example, the commercial capsules manufactured by Yamanouchi Europe, display the following release of tamsulosin at 2
10 hours elapsed time: more than 60% release in SIF, more than 75% release in FaSSIF while less than 40% is released in FeSSIF and less than 20% is released in SGF (see Figure 1). This divergence of results in the four media, being too fast at pH 6.8 and too slow (delayed release) at pH 1.2, indicates a possible reason for variability in plasma concentration of tamsulosin as indicated before; e.g., because of different
15 gastric emptying and/or changing of gastrointestinal pH. Of course this more rapid release in FaSSIF corresponds well with the *in vivo* observations of a quicker T_{max} and a higher C_{max} in a fasting state than in a fed state. Accordingly, preferred tablets of the present invention which exhibit not more than 60% tamsulosin release in each of SIF, FaSSIF, and FeSSIF, preferably also in SGF, have a better food effect, i.e., less
20 difference between fed and fasted conditions, than the commercial capsules.

Preferably the tamsulosin tablets release 20% to 60% of the tamsulosin during the first 2 hours of the dissolution test in each of SIF, FaSSIF, and FeSSIF. More

preferably, the amount of tamsulosin released at 2 hours in FeSSIF is at least 40%, more preferably at least 50%, still more preferably at least 60% of the amount of tamsulosin released at 2 hours in FaSSIF, under the same paddle speed conditions, preferably at 100 rpm. The tablet is preferably a once daily dose tablet, which exhibits
5 a dissolution profile in SIF within the following ranges:

<40 % in 30 minutes

20-60 % in 2 hours

>75 % in 6 hours

using USP apparatus 2, paddles at 100 rpm. More preferably the tablet also exhibits a
10 profile within the above ranges in at least one of, and most preferably both of, FaSSIF and FeSSIF. In some embodiments, the tablet also exhibits a profile within the above ranges in SGF. It should be understood that in meeting the above ranges the dissolution profile in each media need not be identical to each other, although such is contemplated as an embodiment of the invention.

15 For clarity, the amount or percentage of tamsulosin released at a stated time refers to the cumulative total amount of tamsulosin released from the tablet from the start of the dissolution test up to the stated time. The amount released is determined as the average of the results from six trials; e.g. six tablets, for each media or condition. While apparatus 2 and various conditions have been specified, such is not meant to
20 imply that the same or similar release profiles can not be obtained using different apparatus, such as USP apparatus 1 (basket), or different conditions, such as more or

less media, etc. Rather, the above defined apparatus and conditions serve as a convenient way to characterize the inherent properties of the tablets of the invention.

That improved food effect could be obtained is surprising given the performance of the commercial capsule product. In general, the degree of food effect
5 is governed by the type and solubility of the active, the amount/concentration of active, the type and concentration of polymer, and the total mass of the composition. That a modified release low dose tamsulosin tablet having a polymeric matrix could be formulated with reduced food effect, especially without a coating, is unexpected.

The tamsulosin present in the tablet is normally the (R)-enantiomer of
10 tamsulosin but the (S)-enantiomer as well as mixtures of the two in various proportions including equimolar or racemic mixtures are also included within the meaning of tamsulosin or a pharmaceutically acceptable salt thereof. Examples of useful tamsulosin pharmaceutically acceptable salts include tamsulosin hydrochloride, tamsulosin hydrobromide, tamsulosin methane sulfonate, tamsulosin tosylate,
15 tamsulosin besylate, tamsulosin acetate, tamsulosin maleate, tamsulosin tartrate, and tamsulosin citrate. Typically the hydrochloride salt is used.

The amount of tamsulosin active material present in the tablet is relatively low, generally less than 5%, typically 0.1 to 1.5 %. As used herein all percentages refer to weight percent based on the entire weight of the tablet without taking into account any
20 coating thereon, unless otherwise indicated. Typically the amount of tamsulosin active material is within the range of 0.1 to 1.2 %, more typically 0.2 to 1.0 %, preferably 0.2 to 0.8 %, and in many embodiments 0.3 to 0.6 %. In absolute terms, the

amount of tamsulosin active material is within the range of 0.1 to 10 mg, generally within the range of 0.1 to 1.2 mg, typically 0.3 to 1.2 mg, and preferably 0.3 to 0.8 mg, expressed in terms of the amount of free base. For example, 0.4 mg of tamsulosin HCl is a preferred amount of tamsulosin which corresponds to 0.367 mg of tamsulosin free
5 base. A preferred embodiment of the present invention contains 0.4 mg +/- 0.04 of tamsulosin HCl or multiples thereof; i.e., 0.2 or 0.8 mg of tamsulosin HCl.

The tablets of the present invention further contain a polymeric matrix. Specific examples of suitable polymeric materials include water swellable cellulosic derivatives such as hydroxypropylmethyl cellulose (HPMC), carboxymethyl cellulose,
10 cellulose acetate, hydroxyethyl cellulose, hydroxypropyl cellulose; sodium alginate; acrylates, methacrylates and co-polymers thereof with various co-monomers; and polyvinyl pyrrolidones.

In particular, it has been surprisingly found that while acrylates and methacrylates such as Eudragits® (Rohm) as well as celluloses can provide pH
15 independent release, the celluloses generally provide for better food effect properties. Hydroxyethyl cellulose, hydroxypropyl cellulose, cellulose acetate, sodium alginate, carboxymethyl cellulose and hydroxypropyl methylcellulose (HPMC) are preferred, with HPMC being the most preferred. The amount of HPMC is generally within the range of 10 to 90 %, typically 20 to 60%, preferably 25 to 40 %, more preferably 30 to
20 40%, still more preferably 30 to 35 %, based on the total weight of the tablet.

The tablets typically contain additional pharmaceutically acceptable excipients, such as diluents, binders, lubricants, glidants, colorants, preservatives, pH-adjusters,

etc. The excipients are selected based on the desired physical aspects of the final form, the desired release rate of the active substance from the composition after its ingestion, and the ease/cost of manufacture. In general the tablets of the present invention contain in addition to the polymeric matrix, at least one carbohydrate and/or
5 compressible diluent. Carbohydrates include lactose, mannitol, maltodextrin, cyclodextrins, dextrates, and dextrin. Compressible diluents include any pharmaceutically acceptable diluent that is suitable for direct compression especially calcium phosphates such as calcium hydrogen phosphate dihydrate and anhydrate forms.

10 In a preferred embodiment of the present invention, the tablet comprises HPMC and a calcium phosphate such as dicalcium phosphate anhydrate. This embodiment preferably additionally contains a carbohydrate such as lactose anhydrate. A lubricant such as magnesium stearate is also preferably included. The relative amounts are not particularly limited, but it is preferred that these two or three
15 excipients (cellulosic polymer, diluents, and lubricant) comprise the majority of the excipients, such as 95% or more. For example, tablets can comprise 25 to 45% HPMC, 0-50% calcium phosphate (or other insoluble diluent), and 0 to 50 % lactose (or other soluble diluent). The following amounts are preferred: 25 to 40% HPMC, 25-40% calcium phosphate, and 25 to 40 % lactose. More preferably the tablet
20 contains about 30 to 40 % HPMC. Substantially equal amounts of HPMC, calcium phosphate and lactose, i.e. each around 30 to 35 % for a total of 90 to 99.9% is a particularly preferred embodiment. Additional excipients, including a lubricant, etc.

may also be present. This preferred tablet formulation generally exhibits the preferred dissolution profiles described-above.

The tablet of the invention is preferably a monolithic tablet, i.e. a tablet which does not disintegrate after ingestion to form a plurality of smaller particles from which
5 the active component is finally released. Instead, the product erodes in the body and/or drug diffuses through the polymer gel releasing the active substance. Thus, in a monolithic tablet embodiment, none of the excipients used in the manufacturing process of the invention should serve as a disintegrant.

Any of the tablets may be coated such as with an enteric coat or simply for
10 color or stability reasons. For therapeutic purposes, bioabsorption of tamsulosin in body fluids should preferably proceed in the small intestines. Accordingly, the tablets of the invention may also be protected by a suitable gastro-resistant coating which delays the onset of release of the active component from the tablet matrix during the passage thereof in the stomach, but this is not necessary to obtain the desired profiles.
15 Examples of such suitable material for gastro-resistant coating are cellulose acetate phthalate (CAP) (Aquacoat CPD™), co-processed polyvinyl acetate phthalate (PVAP) (Suretetic™), cellulose acetate trimellitate (CAT), Eudragit-type polymers (acrylic - methacrylic acid copolymers), hydropropyl methyl cellulose acetate succinate (HPMCAS).

20 The release property of the coating may be tested also by the same dissolution tests of the uncoated tablets. The preferred properties of a coated tablet are, e.g.:

- Dissolution of the dosage form in SGF, a maximum of 20 % of tamsulosin is released in 2 hours.

- In the other media, the coated tablets should comply with the same dissolution profile as specified above.

5 The tablets of the present invention can be used directly as a unit dosage form, with or without coating, or two or more tablets can be combined such as in a capsule to form a unit dose. The unit dosage form contains an effective amount of tamsulosin for treating or ameliorating the disease, symptoms, and/or or conditions associated with BPH, hypertension, or congestive heart failure, generally from 0.01 to 10.0 mg, 10 preferably 0.1 to 1 mg, in terms of the free base. Preferable are unit doses comprising 0.2, 0.4 or 0.8 mg tamsulosin hydrochloride per se. A unit dose is normally taken from 1 to 3 times daily, preferably once a day as mentioned above. In the case of a capsule, a sufficient number of tablets are provided based on the concentration of the tamsulosin active material therein, so as to provide an effective amount.

15 Taking the usual therapeutic dose of tamsulosin into consideration, a tablet with a total mass of not more than 400 mg and normally between 10 and 300 mg are preferred. As the therapeutic dose of tamsulosin is relatively low, the overall weight of the tablet is advantageously kept as low as possible. Low overall weight of a tablet increases the relative content of tamsulosin in the tablet and thus improves the content 20 uniformity. Furthermore, a small tablet will have a similar rate of the gastro-intestinal transit as the granulated product; thus, results obtained from in-vitro dissolution tests may better predict the actual bioequivalence with the marketed multiparticulate

product. From this aspect, preferred tablet weight within the invention is from 25 to 250 mg, more preferably 40 to 200 mg, though it is not limited to this range. The most preferred tablet weight is within the range of 80 to 100, especially approximately 100 mg.

5 Accordingly, the tablets of the invention may be either small, whereby –
whenever produced in a circular shape- the average diameter thereof is from about 1.5 to about 2.5 mm, or they may be produced as normal tablets, with an average diameter of between 2.5 and 15 mm, more usually 2.5 to 10 mm. Apart from a circular shape, tamsulosin compositions may be compressed into oval, round biconvex, pentagonal
10 circumcircle or other suitable tablet shape.

 Tablets of the invention comprising unit dosage amount of tamsulosin may be delivered for immediate use in a suitable package unit comprising advantageously from 5 to 100 tablets. Such package may comprise a blister pack comprising advantageously 10, 14, 20, 28 or 30 tablets, or a plastic or glass container/bottle
15 containing the same amount (5 to 100) of tablets. Any suitable pharmaceutically acceptable package material may be used in production the package unit.

 The tablets of the present invention can be made by any suitable process of tableting. For example, the tablets can be made by wet granulation wherein the granules are first formed and then, optionally with the addition of further excipient(s)
20 compressed into a tablet. Alternatively, the tablets can be made by dry processes such as direct compression or dry granulation, the latter sometimes being referred to as dry compaction. Preferably the tablets are made by a dry technique in view of

manufacturing ease and economy. Because of the small amount of tamsulosin present in the tablet, it is preferred that multiple blending and/or milling steps be carried out in any dry process.

Tablets for oral administration of tamsulosin according to the invention may be used in the management of functional treatment of symptomatic benign prostate hypertrophy or hyperplasia (BPH) or other disorders treatable by tamsulosin (the Disorders). Accordingly, the present invention further provides a method for treating the symptoms of benign prostatic hyperplasia which comprises administering to a patient in need thereof one or more of any of the above-described tablets. The tablets can be administered in a single capsule.

Tablet compositions of the invention may be also used in medical applications in combination with other agents. The combination may be realized in a form of single combination preparation or by separate administration of drugs containing the above agents.

The invention is further illustrated by the following non-limiting Examples.
Reference Example

Commercially available tamsulosin hydrochloride capsules were obtained in Europe and subjected to dissolution testing, the average of six trials, in each of SGF, SIF, FaSSIF, and FeSSIF in 500 ml of each media at paddle speed 100 rpm in USP apparatus 2 at 37 °C. The amount of drug released was determined by an HPLC method using an HPLC Agilent 1100 system. The detection was made with UV at 230 nm. The results, shown in figure 1, indicate that at 2 hours elapsed time: less than

20% tamsulosin is released in SGF, more than 60% tamsulosin is released in SIF, more than 75% tamsulosin is released in FaSSIF, and less than 40% tamsulosin is released in FeSSIF.

5 Example 1

Three batches of monolithic tablets were made by progressive mixing and direct compression with the following characteristics:

a) Tablet composition

		(%)
Tamsulosin hydrochloride	0.4 mg	0.5
Lactose anhydrous	26.4 mg	33.0
Dicalcium phosphate anh.	26.4 mg	33.0
Hypromellose (HPMC)	26.4 mg	33.0
Magnesium stearate	0.4 mg	0.5
Total	80 mg	100

- 10 The difference between batches was only in the viscosity value of hypromellose selected:

Batch A contained METHOCEL K4M CR PREMIUM

Batch B contained METHOCEL K15M CR PREMIUM

Batch C contained METHOCEL K100M CR PREMIUM

15 b) Modus operandi

Tamsulosin hydrochloride was blended (15 min) with anhydrous lactose in a 1:9 ratio (10% of active substance), milled (15 seconds) and blended again (5 min). This

preblend was then mixed with the rest of the lactose, dicalcium phosphate and hypromellose (10 min), and finally magnesium stearate was added and mixed (5 min) to form the precompression blend. This progressive mixing system provided tamsulosin homogeneity in the preblend of 97.2-100.4% and in the precompression blend of 88.1-98.6%). Compression was performed in a Korsch EK0 press at standard speed and pressure.

c) Characterization of the produced tablets

Batch	Weight (mg)	Hardness (N)	Height (mm)	Diameter (mm)	Assay (%)
A	82.8	52	2.63	5.98	93.6
B	83.5	38	2.69	5.99	88.1
C	81.8	52	2.66	5.99	98.6

d) Dissolution studies

10 Dissolution tests were performed using standard USP apparatus 2, paddles at 50 rpm in 500 ml of SIF. The drug released was determined by an HPLC method using an HPLC Agilent 1100 system. The analysis was performed with a guard column and a C₁₈ analytical column, using an isocratic elution mode, with phosphate buffer pH 6.5 and acetonitrile (65:35) as eluents. The detection was made with UV at 230 nm.

15 Results comply with the following specification:

<40 % in 30 minutes

20-60 % in 2 hours

>75 % in 6 hours

Example 2

Three batches of monolithic tablets were made by progressive mixing and direct compression with the following characteristics:

5 a) Tablet composition

	D	E	F
Tamsulosin hydrochloride	0.4 mg	0.4 mg	0.4 mg
Lactose anhydrous	35.2 mg	30.8 mg	22.0 mg
Dicalcium phosphate anh.	35.2 mg	30.8 mg	22.0 mg
Hypromellose (HPMC)	8.8 mg	17.6 mg	35.2 mg
Magnesium stearate	0.4 mg	0.4 mg	0.4 mg
Total	80 mg	80 mg	80 mg

The difference between batches was only in the concentration of hypromellose used:

Batch D contained 11% METHOCEL K100M CR PREMIUM

Batch E contained 22 % METHOCEL K100M CR PREMIUM

10 Batch F contained 44 % METHOCEL K100M CR PREMIUM

b) Modus operandi

Tamsulosin hydrochloride was blended (15 min) with anhydrous lactose in a 1:9 ratio (10% of active substance), milled (15 seconds) and blended again (5 min). This preblend was then mixed with the rest of the lactose, dicalcium phosphate and

15 hypromellose (10 min), and finally magnesium stearate was added and mixed (5 min).

Compression was performed in a Korsch EK0 press.

c) Characterization of the produced tablets

Batch	Weight (mg)	Hardness (N)	Height (mm)	Diameter (mm)	Assay (%)
D	80.5	19	2.65	6.0	91.9
E	80.4	22	2.74	6.0	94.1
F	80.3	22	2.97	6.0	90.5

d) Dissolution studies

Dissolution tests were performed using USP apparatus 1, baskets at 100 rpm and USP apparatus 2, paddles, at 50 rpm, both in 500 ml of SIF. The drug released was determined by an HPLC method using an HPLC Agilent 1100 system. The analysis was performed with a guard column and a C₁₈ analytical column, using an isocratic elution mode, with phosphate buffer pH 6.5 and acetonitrile (65:35) as eluents. The detection was made with UV at 230 nm.

Results vary according to HPMC concentration, and in each condition, there is a wide range of curves complying with the intended specification. These results can be extrapolated to other bio-relevant dissolution conditions.

Example 3

Two batches of monolithic tablets were made by progressive mixing and direct compression with the following characteristics:

a) Tablet composition

		(%)
Tamsulosin hydrochloride	0.4 mg	0.5
Lactose anhydrous	25.6 mg	32.0

Dicalcium phosphate anh.	25.6 mg	32.0
Hypromellose (HPMC)	28.0 mg	35.0
Magnesium stearate	0.4 mg	0.5
Total	80 mg	100

The differences between both batches were mainly scaling-up, mixing times and physical parameters.

Batch G scaled-up to 20000 units

5 Batch H scaled-up to 40000 units

b) Modus operandi

Tamsulosin hydrochloride was blended (Turbula; 15 min) with anhydrous lactose in a 1:9 ratio (10 % of active substance), milled (IKA; 30 seconds) and blended again (Turbula; 5 min). This pre-blend was then mixed with the rest of the lactose, dicalcium phosphate and hypromellose (Bohle LM40). Three progressive mixing times (15, 30 and 45 minutes) were evaluated for batch D and homogeneity was excellent in all cases (tamsulosin assay of 101.2 %, 101.7 % and 102.1 %). Batch E was mixed for only 10 minutes and acceptable homogeneity was also reached. Sieving of dry blends and excipients was done as required to obtain homogeneity. Finally magnesium stearate was sieved, added and mixed (Bohle LM40; 5 min). The precompression blends were compressed in either an eccentric press Korsch EK0 or in a rotary press Korsch XL100 (about 15000-30000 tablets). Compression performed in Korsch XL100 instrumented rotary press was done at high speeds with standard pre-

compression and pressure. Tablet hardness in both batches was changed to study dissolution performance.

c) Characterization of the produced tablets

Batch	Weight (mg)	Hardness (N)	Height (mm)	Diameter (mm)	Assay (%)
G	80.9	85	2.55	6.00	103.2
H	76.4	39	2.38	5.97	98.2

5 d) Dissolution studies

Dissolution tests were performed using standard USP apparatus 2, paddles at 100 rpm in 500 ml of SGF, SIF, FaSSIF and FeSSIF. The drug released was determined by an HPLC method using an HPLC Agilent 1100 system. The analysis was performed with a guard column and a C₁₈ analytical column, using an isocratic elution mode, with
 10 phosphate buffer pH 6.5 and acetonitrile (65:35) as eluents. The detection was made with UV at 230 nm. The corresponding curves are given in Figures 2 (G) and 3 (H).

Results in SGF and SIF comply with the following specification:

15 <40 % in 30 minutes
 20-60 % in 2 hours
 >75 % in 6 hours

e) coating

These tablets were then coated with an enteric polymer (polymethacrylate type C) based on Eudragit L30D55, with additives including triethylcitrate and talc, or with Acryl-Eze ® (available from Colorcon).

5

f) Dissolution studies

Dissolution tests of the coated batches were performed using standard USP apparatus 2, paddles at 100 rpm in 500 ml of SGF, SIF, FaSSIF and FeSSIF. The drug released was determined by an HPLC method using an HPLC Agilent 1100 system. The analysis was performed with a guard column and a C₁₈ analytical column, using an isocratic elution mode, with phosphate buffer pH 6.5 and acetonitrile (65:35) as eluents. The detection was made with UV at 230 nm.

The corresponding curves are given in Figures 4 (coated G) and 5 (coated H).

Results in SIF comply with the following specification:

15

<40 % in 30 minutes

20-60 % in 2 hours

>75 % in 6 hours

20 Example 4

Two batches of tablets were manufactured by a process that includes dry compaction, milling, mixing and compression.

a) Tablet composition

	I	J
Tamsulosin hydrochloride	0.4 mg	0.4 mg
Lactose	65.6 mg	215.6 mg
Hypromellose (HPMC)	33.0 mg	33.0 mg
Magnesium stearate	1.0 mg	1.0 mg
Total	100 mg	250 mg

Batch I: Monolithic tablet, 6 mm diameter. Contains 33.0% of HPMC K15M P

Batch J: Monolithic tablet, 9 mm diameter. Contains 13.2% of HPMC K15M P

b) Modus operandi

- 5 Tamsulosin was blended (15 min), milled (15 seconds) and blended again (5 min), with anhydrous lactose in a 1:9 ratio (10% of active substance). This preblend was then mixed with the rest of lactose, hypromellose and 25% of magnesium stearate (10 min), compacted in Chilsonator (Fitz-Patrick) and milled in Fitz-Mill (Fitz-Patrick), finally the rest of magnesium stearate (75%) was added and then mixed (15 min).
- 10 Compression was performed in a Korsch EK0 press at standard speed and pressure.

c) Characterization of the produced tablets.

Batch	Weight (mg)	Hardness (N)	Height (mm)	Diameter (mm)	Lubrication coefficient
I	103.3	31	3.42	6.0	98.4
J	251.6	42	3.71	9.0	100

Example 5

Two batches of tablets were manufactured with different active concentration, tablet geometries and total mass.

a) Tablet composition

	K	L	M
Tamsulosin hydrochloride	0.4 mg	0.2 mg	0.2 mg
Lactose anhydrous	25.6 mg	12.9 mg	129.0 mg
Dicalcium phosphate anh.	25.6 mg	12.7 mg	128.8 mg
Hypromellose (HPMC)	28.0 mg	14.0 mg	140.0 mg
Magnesium stearate	0.4 mg	0.2 mg	2.0 mg
Total	80 mg	40 mg	400 mg

5 b) Modus operandi

Micronised tamsulosin was blended progressively with anhydrous lactose. This preblend was then mixed with the rest of lactose and hypromellose and after with magnesium stearate to provide in all cases enough homogeneity. Compression was performed in a Korsch EK0 press at standard speed and pressures.

10 c) Characterization of the produced tablets

Batch	Weight (mg)	Hardness (N)	Height (mm)	Diameter (mm)	Assay (%)
K (special shape)	84.1	53	2.65	n.a.	90.5
L	40.6	36	2.01	5.00	94.1
M	398.1	132	4.57	10.05	90.5

Example 6

A batch of monolithic tablets was manufactured to check dissolution specifications.

a) Tablet composition

		(%)
Tamsulosin hydrochloride	0.4 mg	0.5
Lactose anhydrous	31.6 mg	39.5
Dicalcium phosphate anh.	31.6 mg	39.5
Hypromellose (HPMC)	16.0 mg	20.0
Magnesium stearate	0.4 mg	0.5
Total	80 mg	100

Batch N scale-up was performed using micronised drug substance and less mixing steps. 40000 units were manufactured.

5 b) Modus operandi

Micronised tamsulosin hydrochloride was blended (Bohle LM40; 15 min) with hypromellose. This pre-blend was then mixed with lactose and dicalcium phosphate (Bohle LM40; 15 minutes). Sieving of dry blends and excipients was done as required to obtain homogeneity. Finally magnesium stearate was sieved, added and mixed, two
10 times (Bohle LM40; 5 and 15 minutes).

The precompression blends were then compressed. Compression was performed in a Korsch XL100 instrumented rotary press was done at high speeds with standard pre-compression and pressure.

Characterisation of the tablets is presented below:

c) Characterization of the produced tablets

Batch	Weight (mg)	Hardness (N)	Height (mm)	Diameter (mm)	Assay (%)
N	80.7	47	2.50	6.05	104.0

d) coating

This tablets were then coated with an enteric polymer (Acryl-Eze ® available from

5 Colorcon).

e) Dissolution studies

Dissolution tests of the coated batches were performed using standard USP apparatus 2, paddles, at 100 rpm in 500 ml of SGF, SIF, FaSSIF and FeSSIF. The drug released was determined by an HPLC method using an HPLC Agilent 1100 system. The
10 analysis was performed with a guard column and a C₁₈ analytical column, using an isocratic elution mode, with phosphate buffer pH 6.5 and acetonitrile (65:35) as eluents. The detection was made with UV at 230 nm.

The corresponding curves are given in Figure 6.

Results in all media comply with the following specification:

15

<40 % in 30 minutes

20-60 % in 2 hours

>75 % in 6 hours

The invention having been described, it will be readily apparent to those skilled in the art that further changes and modifications in actual implementation of the concepts and embodiments described herein can easily be made or may be learned by practice of the invention, without departing from the spirit and scope of the

5 invention as defined by the following claims.

We Claim:

1. A pharmaceutical tablet comprising a tablet matrix having dispersed therein 0.1 to 10 mg of tamsulosin or a pharmaceutically acceptable salt thereof, and optionally having an enteric coating over said matrix, wherein said tablet is a modified release tablet and has a dissolution profile such that in each of the media SIF, FaSSIF, and FeSSIF, said tablet releases not more than 60% of said tamsulosin at 2 hours elapsed time in USP 2 apparatus using 500 ml of said media at 50-100 rpm paddle speed.
2. The pharmaceutical tablet according to claim 1, wherein said dissolution profile is measured using 100 rpm paddle speed.
3. The pharmaceutical tablet according to claim 1 or 2, wherein said dissolution profile exhibits a release of at least 20% in each of said media at 2 hours elapsed time.
4. The pharmaceutical tablet according to claim 1-3, wherein said tablet has a dissolution profile wherein the amount of tamsulosin released at 2 hours in FeSSIF media is at least 50% the amount released at 2 hours in FaSSIF media.
5. The pharmaceutical tablet according to claim 1-4, wherein said tablet has a dissolution profile wherein said tablet releases not more than 60% of said tamsulosin at 2 hours elapsed time in USP 2 apparatus using 500 ml of SGF media at 100 rpm paddle speed.
6. The pharmaceutical tablet according to claim 1-5, wherein said dissolution profile includes releasing less than 40% of the tamsulosin in 30-minutes, 20 – 60% of the tamsulosin in 2 hours, and greater than 75% of the tamsulosin in 6 hours in USP 2 apparatus using 500 ml of SIF media at 100 rpm paddle speed.

7. The pharmaceutical tablet according to claim 1-6, wherein said dissolution profile includes releasing less than 40% of the tamsulosin in 30 minutes, 20 – 60% of the tamsulosin in 2 hours, and greater than 75% of the tamsulosin in 6 hours in USP 2 apparatus using 500 ml of SGF media at 100 rpm paddle speed.
8. The pharmaceutical tablet according to claim 1-7, wherein said tablet has an enteric coating.
9. The pharmaceutical tablet according to claim 1-7, wherein said tablet does not have an enteric coating.
10. The pharmaceutical tablet according to claim 9, wherein said tablet is uncoated.
11. The pharmaceutical tablet according to claim 1-10, wherein said tablet matrix comprises a water swellable cellulosic derivative.
12. The pharmaceutical tablet according to claim 11, wherein said tablet matrix comprises hydroxypropyl methylcellulose.
13. The pharmaceutical tablet according to claim 11 or 12, wherein said tablet comprises said hydroxypropyl methylcellulose in an amount within the range of 10 wt% - 90wt%.
14. The pharmaceutical tablet according to claim 13, wherein said tablet comprises said hydroxypropyl methylcellulose in an amount within the range of 25 wt% - 40wt%.
15. The pharmaceutical tablet according to claim 14, wherein said tablet comprises said hydroxypropyl methylcellulose in an amount within the range of 30 wt% - 35 wt%.

16. The pharmaceutical tablet according to claim 1-15, wherein said tamsulosin or pharmaceutically acceptable salt thereof is contained in an amount of 0.2 to 1.0 %.
17. The pharmaceutical tablet according to claim 16, wherein said tamsulosin or pharmaceutically acceptable salt thereof is contained in an amount of 0.2 to 0.8 %.
18. The pharmaceutical tablet according to claim 1-17, wherein said tamsulosin or pharmaceutically acceptable salt thereof is tamsulosin hydrochloride and said tamsulosin hydrochloride is contained in an amount of 0.4mg +/- 0.04.
19. The pharmaceutical tablet according to claim 1-18, which further comprises at least one pharmaceutically acceptable excipient selected from the group consisting of a carbohydrate and a compressible diluent.
20. The pharmaceutical tablet according to claim 19, which further comprises lactose.
21. The pharmaceutical tablet according to claim 19 or 20, which comprises a calcium phosphate.
22. The pharmaceutical tablet according to claim 1-21, which comprises lactose, HPMC, a calcium phosphate, and magnesium stearate.
23. The pharmaceutical tablet according to claim 1-22, wherein said tablet is a once daily dose tablet.
24. A monolithic pharmaceutical tablet, comprising 0.1 to 10 mg of tamsulosin or a pharmaceutically acceptable salt thereof, 10 wt% - 90 wt% hydroxypropyl methylcellulose, and a total tablet weight of 10 to 300 mg.

25. The monolithic tablet according to claim 24, wherein said total tablet weight is within the range of 25 to 250 mg.
26. The monolithic tablet according to claim 25, wherein said total tablet weight is within the range of 80 to 100 mg.
27. The monolithic tablet according to claim 24-26, comprises said hydroxypropyl methylcellulose in an amount within the range of 25 wt% - 40 wt%.
28. The monolithic tablet according to claim 27, comprises said hydroxypropyl methylcellulose in an amount within the range of 30 wt% - 40 wt%.
29. The monolithic tablet according to claim 24-28, wherein said tablet comprises said hydroxypropyl methylcellulose in an amount within the range of 30 wt% - 35 wt%.
30. The monolithic tablet according to claim 24-29, wherein said tablet further comprises a calcium phosphate, lactose, mannitol, or a combination thereof.
31. The monolithic tablet according to claim 30, wherein said tablet comprises dibasic calcium phosphate anhydrous.
32. The monolithic tablet according to claim 24-31, which does not contain an enteric coating.
33. A unit dosage form for treating or ameliorating the conditions of benign prostatic hyperplasia comprising an effective amount of one or more tablets according to claim 1-32.
34. The unit dosage form according to claim 33, which comprises two or more of said tablets in a capsule.
35. A method for treating the symptoms of benign prostatic hyperplasia, which comprises administering to a patient in need thereof one or more tablets according to claim 1-32 or unit dosage according to claims 33 or 34.

36. The method according to claim 35, wherein said one or more tablets are contained in a single capsule administered to said patient.

FIGURE 1

FIGURE 1




FIGURE 2

FIGURE 2




FIGURE 3

FIGURE 3




FIGURE 4

FIGURE 4




FIGURE 5

FIGURE 5





FIGURE 6

FIGURE 6



INTERNATIONAL SEARCH REPORT

PCT/NL 02/00710

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/18 A61K9/20 A61K9/28 A61K9/48 A61P13/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, MEDLINE, CHEM ABS Data, PASCAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 772 475 A (FUKUI MUNE0 ET AL) 20 September 1988 (1988-09-20) cited in the application	33,34
A	column 5 -column 11; figures 1,2; examples	1-32,35, 36
X	EP 1 088 551 A (YAMANOUCHI PHARMA CO LTD) 4 April 2001 (2001-04-04)	33,34
A	page 3, line 23-26	1-32,35, 36



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

6 February 2003

Date of mailing of the international search report

19/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Zimmer, B

INTERNATIONAL SEARCH REPORT

PCT/NL 02/00710

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT – Method for treatment of the human or animal body by therapy Although claims 35 and 36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/NL 02/00710

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4772475	A	20-09-1988	CA 1264293 A1	09-01-1990
			DE 3650657 D1	02-01-1998
			DE 3688532 D1	15-07-1993
			DE 3688532 T2	23-09-1993
			EP 0194838 A2	17-09-1986
			EP 0533297 A1	24-03-1993
			ES 8800041 A1	01-01-1988
			JP 2036811 C	28-03-1996
			JP 7072129 B	02-08-1995
			JP 62000009 A	06-01-1987
			KR 9307245 B1	04-08-1993
			ZA 8601565 A	29-10-1986
EP 1088551	A	04-04-2001	AU 4392199 A	17-01-2000
			CA 2336151 A1	06-01-2000
			EP 1088551 A1	04-04-2001
			CN 1312711 T	12-09-2001
			WO 0000187 A1	06-01-2000
			JP 2000080032 A	21-03-2000